Sifel says financing should bring Inventiva’s Lani ‘over the finish line’

Stifel says that removing the biggest overhang from its stock, Inventiva has finally completed a $410M financing that will allow it to complete the Lani Phase 3 NATiV3 pivotal program for MASH, complete regulatory review, and even launch the drug commercially upon approval. The financing comes in several tranches-contingent upon satisfaction of various shareholder votes, independent safety reviews, limited discontinuations, and ultimately release of top-line data. But based on strong and consistent indications from multiple Phase 2 trials and various DSMB recommendations, Stifel thinks Buy-rated Inventiva will largely be able to satisfy these requirements.